Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2011. The report details a specific share repurchase transaction executed on May 9, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Repurchased: 450,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,316.50 pence; lowest price paid was 1,302.00 pence.
- Treasury Shares Held: 493,224,284 shares (8.72% of total issued share capital; 9.55% of total voting rights).
- Shares in Issue: 5,163,955,067 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 450,000 repurchased shares. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Confirm the total number of shares in issue (5,163,955,067) for calculating disclosure thresholds under FSA rules.
- Verify the updated Treasury share count and its percentage of total voting rights (9.55%).
- Note that the repurchased shares were cancelled, permanently reducing the company's share capital.